# Diag-Nose Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/diag-nose-medical-pty

- Industry: Biotechnology
- Headquarters: Port Melbourne, Australia
- Website: www.diag-nose.io
- Total disclosed funding: $3.1M
- Latest round: Seed (Jan 29, 2025)
- Investors on record: 2

## About

Founded in 2020 and based in Australia, Diag-Nose Medical Pty Ltd focuses on respiratory diagnostics and therapeutics. The firm has completed a total of 2 deals, with the most recent being on September 1, 2025, when it raised USD 3 mn in a Grant round led by Cooperative Research Centres Projects (CRCP) Grants. Eldin Rostom (CEO), Dr. David Yen, Dr. Josie Xu, and Dr. Brian Wang, founded the firm.

Diag-Nose Medical offers solutions for respiratory care, focusing on the relationship between the lungs and nasal passages. The company's core offering includes advanced immune diagnostics and therapies tailored for respiratory patients, utilizing an AI-driven approach to match individuals with appropriate drug treatments based on their biological makeup. This precision medicine framework aims to support respiratory treatments by decoding the underlying biology of the immune system and utilizing biomarkers to guide therapy selection. Diag-Nose targets a diverse client base that includes healthcare providers, research institutions, and pharmaceutical partners, aiming to serve patients globally, particularly in markets such as Australia and the United States. 

Diag-Nose Medical generates revenue through a structured model that emphasizes partnerships with healthcare providers and research organizations, allowing for direct access to patients and clinical data. The company engages in B2B transactions, wherein healthcare institutions subscribe to its diagnostic services or collaborate on research initiatives. The pricing structure reflects the advanced technology and research underpinning its offerings, encompassing fees for personalized diagnostic assessments and the development of bespoke therapeutic solutions. 

In?September 2025,?Diag-Nose Medical Pty Ltd?received?USD 3 million?in?grant?funding to develop RhinoMAP, an AI-based platform for treating respiratory diseases. The company aims to expand its market presence further into the Australian and US healthcare sectors while exploring additional global markets.

## Funding rounds

- Seed, Jan 29, 2025, $3.1M — Breakthrough Victoria, Radar Ventures

## Investors

- Breakthrough Victoria — Seed
- Radar Ventures (https://capitalatlas.ai/funds/radar-ventures) — Seed